Autres langues SOPHiA GENETICS SA Börse Stuttgart

Actions

90B

CH1125843347

Equipement et technologie médicale avancés

Temps Différé Börse Stuttgart 09:33:35 10/09/2026			Varia. 5j.	Varia. 1 janv.
6,600 ^EUR	0,00%		-5,71%	+70,10%

04/08	Transcript : SOPHiA GENETICS SA, Q2 2026 Earnings Call, Aug 04, 2026
04/08	Sophia Genetics SA et AstraZeneca concluent une collaboration pour développer des diagnostics compagnons en oncologie de précision	CI

Autres langues

04/08	Sophia Genetics SA and AstraZeneca Enter Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies
04/08	SOPHiA GENETICS SA Raises Earnings Guidance for the Full Year 2026
04/08	AstraZeneca Collaborates With Sophia Genetics on Companion Diagnostics for Oncology Therapies
04/08	SOPHiA GENETICS SA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
04/08	SOPHiA GENETICS Reports Second Quarter 2026 Results
04/08	SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies
22/07	Sophia Genetics Insider Sold Shares Worth $286,099, According to a Recent SEC Filing
21/07	SOPHiA GENETICS to Announce Financial Results for Second Quarter 2026 on August 4, 2026
01/07	Sophia Genetics Insider Sold Shares Worth $506,690, According to a Recent SEC Filing
29/06	Sophia Genetics Insider Sold Shares Worth $298,155, According to a Recent SEC Filing
22/06	SOPHiA GENETICS SA Approves Board Changes
22/06	SOPHiA GENETICS Publishes Results of the 2026 Annual General Meeting
19/06	SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to Purchase Additional Shares
17/06	Sophia Genetics Prices $50 Million Stock Offering
17/06	SOPHiA GENETICS Announces Pricing of $50 Million Public Offering of Ordinary Shares
16/06	Sophia Genetics Launches Proposed Share Offering
16/06	SOPHiA GENETICS Announces Proposed Public Offering of Ordinary Shares
10/06	SOPHiA GENETICS Names Ross Muken as CEO, Nominates Jurgi Camblong as Chairman
10/06	SOPHiA GENETICS Confirms Leadership Transition Ahead of 2026 Annual General Meeting
04/06	SOPHiA GENETICS Signs Strategic Collaboration Memorandum Of Understanding With Meamorial Sloan Kettering Cancer Center
04/06	Sophia Genetics, Memorial Sloan Kettering Plan Precision Oncology Joint Venture
04/06	SOPHiA GENETICS Signs Strategic Collaboration MOU with Leading Global Cancer Center
01/06	SOPHiA GENETICS : and ARC Regulatory Collaborate to Support EU Clinical Trial Assay Development
13/05	Sophia Genetics, Synnovis Partner on UK Blood-Based Cancer Testing
13/05	Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.